Pulmonx Statistics
Total Valuation
Pulmonx has a market cap or net worth of $245.32 million. The enterprise value is $169.52 million.
| Market Cap | 245.32M |
| Enterprise Value | 169.52M |
Important Dates
The next estimated earnings date is Wednesday, July 31, 2024, after market close.
| Earnings Date | Jul 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pulmonx has 38.82 million shares outstanding. The number of shares has increased by 2.83% in one year.
| Shares Outstanding | 38.82M |
| Shares Change (YoY) | +2.83% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 5.26% |
| Owned by Institutions (%) | 95.57% |
| Float | 34.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.36 |
| Forward PS | 2.79 |
| PB Ratio | 2.22 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.95, with a Debt / Equity ratio of 0.37.
| Current Ratio | 6.95 |
| Quick Ratio | 5.96 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.39 |
Financial Efficiency
Return on equity (ROE) is -48.10% and return on invested capital (ROIC) is -39.76%.
| Return on Equity (ROE) | -48.10% |
| Return on Assets (ROA) | -32.60% |
| Return on Capital (ROIC) | -39.76% |
| Revenue Per Employee | $261,627 |
| Profits Per Employee | -$210,509 |
| Employee Count | 279 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 0.94 |
Taxes
In the past 12 months, Pulmonx has paid $633,000 in taxes.
| Income Tax | 633,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.31% in the last 52 weeks. The beta is 0.65, so Pulmonx's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -51.31% |
| 50-Day Moving Average | 7.53 |
| 200-Day Moving Average | 9.91 |
| Relative Strength Index (RSI) | 41.55 |
| Average Volume (20 Days) | 419,114 |
Short Selling Information
The latest short interest is 1.40 million, so 3.60% of the outstanding shares have been sold short.
| Short Interest | 1.40M |
| Short Previous Month | 1.58M |
| Short % of Shares Out | 3.60% |
| Short % of Float | 4.07% |
| Short Ratio (days to cover) | 3.79 |
Income Statement
In the last 12 months, Pulmonx had revenue of $72.99 million and -$58.73 million in losses. Loss per share was -$1.54.
| Revenue | 72.99M |
| Gross Profit | 54.24M |
| Operating Income | -60.07M |
| Pretax Income | -58.10M |
| Net Income | -58.73M |
| EBITDA | -50.29M |
| EBIT | -54.55M |
| Loss Per Share | -$1.54 |
Balance Sheet
The company has $116.37 million in cash and $40.57 million in debt, giving a net cash position of $75.79 million or $1.95 per share.
| Cash & Cash Equivalents | 116.37M |
| Total Debt | 40.57M |
| Net Cash | 75.79M |
| Net Cash Per Share | $1.95 |
| Equity (Book Value) | 110.50M |
| Book Value Per Share | 2.85 |
| Working Capital | 126.64M |
Cash Flow
In the last 12 months, operating cash flow was -$36.76 million and capital expenditures -$1.20 million, giving a free cash flow of -$37.96 million.
| Operating Cash Flow | -36.76M |
| Capital Expenditures | -1.20M |
| Free Cash Flow | -37.96M |
| FCF Per Share | -$0.98 |
Margins
Gross margin is 74.31%, with operating and profit margins of -82.29% and -80.46%.
| Gross Margin | 74.31% |
| Operating Margin | -82.29% |
| Pretax Margin | -79.59% |
| Profit Margin | -80.46% |
| EBITDA Margin | -68.89% |
| EBIT Margin | -74.74% |
| FCF Margin | -52.00% |
Dividends & Yields
Pulmonx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.83% |
| Shareholder Yield | -2.83% |
| Earnings Yield | -23.94% |
| FCF Yield | -15.47% |
Analyst Forecast
The average price target for Pulmonx is $15.25, which is 141.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.25 |
| Price Target Difference | 141.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 20.87% |
| EPS Growth Forecast (5Y) | -16.85% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pulmonx has an Altman Z-Score of -0.62 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.62 |
| Piotroski F-Score | 4 |